Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$20.14 +0.9%	$23.98	$12.21 ▼ $40.70	$559.10M	-0.2	511,663 shs	547,616 shs
KRRO Korro Bio	$20.26 +1.9%	$14.32	$10.29 ▼ $98.00	$186.69M	2.51	143,864 shs	136,802 shs
TSHA Taysha Gene Therapies	$2.94	$2.60	$1.05 ▼ $3.31	$631.10M	0.98	2.85 million shs	2.89 million shs
VIR Vir Biotechnology	$4.52 +1.8%	$5.22	$4.16 ▼ $14.45	$616.79M	1.18	1.07 million shs	1.02 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+0.85%	-4.23%	-25.02%	-0.40%	-41.88%
KRRO Korro Bio	+1.91%	+26.63%	+53.95%	+34.08%	-48.98%
TSHA Taysha Gene Therapies	0.00%	+8.09%	+15.75%	+8.89%	+27.27%
VIR Vir Biotechnology	+1.80%	+5.12%	-16.45%	-1.74%	-46.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAB AnaptysBio	3.1288 of 5 stars	4.4	0.0	3.3	2.5	0.6
KRRO Korro Bio	1.4499 of 5 stars	3.6	1.0	2.3	0.0	0.0
TSHA Taysha Gene Therapies	3.5063 of 5 stars	4.5	2.0	2.9	3.3	0.0
VIR Vir Biotechnology	3.3692 of 5 stars	3.4	2.0	3.1	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.80	Moderate Buy	$46.13	129.02% Upside
KRRO Korro Bio	3.29	Buy	$86.83	328.59% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.29	181.83% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	569.25% Upside

Current Analyst Ratings Breakdown

Latest KRRO, VIR, ANAB, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/13/2025	KRRO Korro Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$153.00 ➝ $147.00
8/13/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$100.00 ➝ $90.00
8/13/2025	TSHA Taysha Gene Therapies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.50 ➝ $8.00
8/12/2025	ANAB AnaptysBio	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $20.00
8/12/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/7/2025	ANAB AnaptysBio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $45.00
7/24/2025	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $80.00
7/24/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$123.16M	4.58	N/A	N/A	($1.60) per share	-12.59
KRRO Korro Bio	$2.27M	83.81	N/A	N/A	$12.26 per share	1.65
TSHA Taysha Gene Therapies	$8.33M	75.76	N/A	N/A	$1.16 per share	2.53
VIR Vir Biotechnology	$74.21M	8.46	N/A	N/A	$6.82 per share	0.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$145.23M	-$4.48	N/A	N/A	N/A	-107.66%	-366.98%	-30.58%	11/4/2025 (Estimated)
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-61.51%	-42.87%	N/A
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,144.97%	-78.44%	-44.82%	N/A
VIR Vir Biotechnology	-$521.96M	-$4.00	N/A	N/A	N/A	-2,895.94%	-50.22%	-40.78%	10/30/2025 (Estimated)

Latest KRRO, VIR, ANAB, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	-$2.74	-$0.20	-$2.74	$0.41 million	$1.46 million
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	-$0.09	-$0.02	-$0.09	$1.61 million	$1.99 million
8/6/2025	Q2 2025	ANAB AnaptysBio	-$1.50	-$1.34	+$0.16	-$1.34	$11.55 million	$22.26 million
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.72	-$0.80	-$0.08	-$0.80	$2.38 million	$1.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	8.22	8.22
KRRO Korro Bio	N/A	5.98	9.41
TSHA Taysha Gene Therapies	0.17	12.48	5.35
VIR Vir Biotechnology	N/A	7.01	7.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
KRRO Korro Bio	13.18%
TSHA Taysha Gene Therapies	77.70%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	33.50%
KRRO Korro Bio	4.60%
TSHA Taysha Gene Therapies	3.78%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	28.00 million	18.62 million	Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable
VIR Vir Biotechnology	580	138.92 million	116.69 million	Optionable

KRRO, VIR, ANAB, and TSHA Headlines

Recent News About These Companies

Leerink Partnrs Issues Optimistic Forecast for VIR Earnings

August 12, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Outlook for VIR Earnings

August 12, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month Low - Here's Why

August 10, 2025 | marketbeat.com

Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)

August 9, 2025 | theglobeandmail.com

Short Interest in Vir Biotechnology, Inc. (NASDAQ:VIR) Rises By 50.7%

August 9, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% Following Weak Earnings

August 8, 2025 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% After Earnings Miss

August 8, 2025 | americanbankingnews.com

Vir Biotechnology Reports Q2 2025 Financial Results

August 7, 2025 | msn.com

Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum

August 7, 2025 | msn.com

Vir (VIR) Q2 Revenue Drops 61%

August 7, 2025 | fool.com

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6, 2025 | businesswire.com

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 6, 2025 | businesswire.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $109,780.00 in Stock

August 5, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Brokerages

August 1, 2025 | marketbeat.com

Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks

July 31, 2025 | genengnews.comG

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025 | businesswire.com

Allianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KRRO, VIR, ANAB, and TSHA Company Descriptions

AnaptysBio NASDAQ:ANAB

$20.14 +0.17 (+0.85%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$20.14 0.00 (-0.02%)

As of 08/15/2025 04:54 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Korro Bio NASDAQ:KRRO

$20.26 +0.38 (+1.91%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$20.82 +0.56 (+2.76%)

As of 08/15/2025 07:58 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$2.94 0.00 (0.00%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.94 0.00 (-0.17%)

As of 08/15/2025 07:26 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Vir Biotechnology NASDAQ:VIR

$4.52 +0.08 (+1.80%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.50 -0.02 (-0.53%)

As of 08/15/2025 07:30 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time